alxo: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Research and development expenses	59,351	-
General and administrative expenses	18,474	-
Impairment of long-lived assets	3,175	-
Total impairment charge	3,175	-
Loss from operations	-81,000	-
Interest income	3,391	-
Interest expense	1,219	-
Other income (expense), net	-19	-
Net loss	-78,847	-
Stock-based compensation	9,873	-
Depreciation and amortization	555	-
Non-cash lease costs	1,333	-
Net accretion of discounts on investments	1,056	-
Accretion of term loan discount and issuance costs	208	-
Impairment charge	3,175	-
Prepaid expenses and other current assets	-705	-
Other assets	5,693	-
Accounts payable	2,090	-
Payable and accrued liabilities due to related party	-149	-
Accrued expenses and other current liabilities	4,150	-
Other non-current liabilities	-1,506	-
Net cash used in operating activities	-65,162	-
Purchase of investments	45,619	-
Maturities of investments	117,135	-
Purchase of property and equipment	163	-
Net cash provided by investing activities	71,353	-
Proceeds from atm offering, net of commissions	372	-
Proceeds from exercise of stock options under equity incentive plan	1	-
Proceeds from issuance of common stock under employee stock purchase plan	15	-
Principal payments on finance leases	704	-
Net cash (used in) provided by financing activities	-316	-
Restricted cash (included in other assets)	-	66
Net increase (decrease) in cash, cash equivalents and restricted cash	5,875	-
Cash and cash equivalents	-	19,302
Cash and cash equivalents at beginning of period	17,633	-
Cash and cash equivalents at end of period	23,508	19,368

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

alxo: the cashflow